AI-powered volumetric analysis for MRI
Cortechs.ai delivers clinically-validated AI tools—NeuroQuant® and others—for automated volumetric analysis, lesion tracking, and MRI diagnostics in neurodegenerative disease, brain tumors, and prostate cancer.
Deep clinical evidence and CPT billing support have made it a trusted tool across over 1,500 hospitals.
Key benefits
- Automated brain segmentation and volumetric reporting in minutes
- Supports lesion tracking for MS, brain tumors, ARIA, PET tracer quantification, and prostate MRI
- CE-marked and FDA-cleared (510(k)), with new regulatory approvals in Canada
- Helps standardise reporting, reduce subjective variability, and support CPT billing codes
Details
- Regulatory: FDA 510(k), CE‑marked; Health Canada approved April 2025
- Applications: Neurology, Oncology, Urology (prostate)
- Modality: MRI (with PET & CT alignment support)
- Body part: Brain (including tumor, MS lesion, ARIA) and prostate
Clinical evidence
- Over 1,500 medical centers use Cortechs.ai tools globally
- CPT codes 0865T/0866T activated 2024—for reimbursable AI-assisted brain MRI analytics
For the latest clinical evidence and updates, visit the company’s official website: https://www.cortechs.ai/
Ask K2AI how Cortechs.ai can deliver rapid, AI-driven volumetric analysis for brain and prostate MRI into your radiology setup.
בניית אתרים JUNAMI